Drugs / INAVAC
INAVAC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06259578 | Jan → Aug 2024 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06272253 | Sep 2023 → Mar 2024 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06282692 | Jun 2023 → May 2024 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INAVAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06272253 ↗ |
| Known as | UA-SARS CoV-2 (Vero Cell Inactivated) | “An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old” NCT06282692 ↗ |
| Known as | Vaksin Merah Putih | “An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old” NCT06282692 ↗1“Immunogenicity and Safety of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster” NCT06259578 ↗ |
| Known as | Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated) | “Immunobridging Study: Immunogenicity and Safety of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) as Heterologue Booster in Adolescent Subjects in Indonesia” NCT06272253 ↗ |
| Modality | Vaccine | “INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine” NCT06259578 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06259578 ↗ |